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Abstract
Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs)
which are converted to dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase
(Ephx2, sEH). To examine the functional role of sEH in the heart, mice with targeted disruption of
the Ephx2 gene were studied. Hearts from sEH null mice have undetectable levels of sEH mRNA
and protein and cannot convert EETs to DHETs. sEH null mice have normal heart anatomy and basal
contractile function, but have higher fatty acid epoxide:diol ratios in plasma and cardiomyocyte cell
culture media compared with wild type (WT). sEH null hearts have improved recovery of left
ventricular developed pressure (LVDP) and less infarction compared with WT hearts after 20 minutes
ischemia. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid
(10 to 100 nmol/L) before ischemia abolishes this cardioprotective phenotype. Inhibitor studies
demonstrate that perfusion with phosphatidylinositol-3 kinase (PI3K) inhibitors wortmannin (200
nmol/L) or LY294002 (5 μmol/L), the ATP-sensitive K+ channel (KATP) inhibitor glibenclamide (1
μmol/L), the mitochondrial KATP (mitoKATP) inhibitor 5-hydroxydecanoate (100 to 200 μmol/L),
or the Ca2+-sensitive K+ channel (KCa) inhibitor paxilline (10 μmol/L) abolishes the cardioprotection
in sEH null hearts. Consistent with increased activation of the PI3K cascade, sEH null mice exhibit
increased cardiac expression of glycogen synthase kinase-3β (GSK-3β) phospho-protein after
ischemia. Together, these data suggest that targeted disruption of sEH increases the availability of
cardioprotective EETs that work by activating PI3K signaling pathways and K+ channels.
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Arachidonic acid (AA), a polyunsaturated fatty acid normally found esterified to cell
membrane glycero-phospholipids, can be released by phospholipases in response to ischemia.
1 Free AA is then available for metabolism by prostaglandin H2 synthases, lipoxygenases, and
cytochrome P450 (CYP) monooxygenases to generate numerous metabolites, collectively
termed eicosanoids.1 CYP epoxygenases metabolize AA to 4 regioisomeric
epoxyeicosatrienoic acids (5,6-, 8,9-, 11,12-, and 14,15-EETs), all of which are biologically
active.1 The actions of EETs are terminated by conversion to the corresponding and less
biologically active dihydroxyeicosatrienoic acids (DHETs) by epoxide hydrolases.2 Two
major epoxide hydrolases are found in mammalian tissues, the microsomal epoxide hydrolase
(mEH) and the soluble epoxide hydrolase (sEH or Ephx2).3 Previous work has demonstrated
that sEH is the main enzyme involved in the in vivo hydrolysis of EETs.4
EETs are important components of many intracellular signaling pathways in both cardiac and
extracardiac tissues. For example, EETs activate large conductance Ca2+-sensitive K+ channels
(BKCa) in vascular smooth muscle cells resulting in hyperpolarization of the resting membrane
potential and vasodilation of the coronary circulation.5 This effect is diminished on hydrolysis
of EETs to DHETs by sEH.6 Other studies have shown that EETs display antiinflammatory,
thrombolytic, and angiogenic properties within the vasculature.7–9 In endothelial cells, EETs
activate mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)-
Akt signaling pathways, increase intracellular cAMP levels, upregulate expression of nitric
oxide synthase, and protect against hypoxia-reoxygenation injury.8–10 In general, the effects
of DHETs on these pathways are less pronounced.7,9 Within the heart, EETs activate cardiac
ATP-sensitive K+ (KATP) channels,11,12 enhance L-type calcium currents,13 and improve
postischemic recovery of left ventricular function.12,14,15 Thus, alteration in the production
or elimination of EETs may affect steady-state cellular levels of these bioactive eicosanoids
in vivo and could potentially influence cardiac function.
Recently, we reported that transgenic mice with cardiac-specific overexpression of human
CYP2J2 had increased cardiomyocyte EET biosynthesis and enhanced postischemic recovery
of left ventricular function.12 The mechanism for the cardioprotection involved activation of
mitochondrial KATP channels and the p42/p44-MAPK pathway.12 To further examine the
cardiac effects of CYP-derived eicosanoids under basal conditions and after ischemia/
reperfusion, and to determine the functional role of sEH in the heart, we evaluated mice with
a targeted disruption of the Ephx2 gene.16 sEH null mice have normal heart anatomy and basal
contractile function, but exhibit improved recovery of left ventricular function after global
ischemia and less infarction. Moreover, our data suggest that this cardioprotection is mediated
by CYP epoxygenase metabolites of AA and involves activation of the PI3K pathway and
K+ channels.
Materials and Methods
For an expanded Material and Methods section, see the online data supplement available at
http://circres.ahajournals.org.
Animals
Mice with the targeted disruption of the Ephx2 gene were obtained from Christopher Sinal
(Dalhousie University, Halifax, NS, Canada).16 These mice, backcrossed onto a C57BL6
genetic background for 5 generations, were used to rederive a new colony at NIEHS by embryo
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transfer. All experiments used male and female mice aged 4 to 6 months, weighing 25 to 35g,
and were approved by the NIEHS Animal Care and Use Committee.
Northern Analysis, Immunoblotting
Northern analysis and immunoblotting were as previously described.12,16 Subcellular
fractions were prepared from frozen mouse hearts. Immunoblots were probed with antibodies
to sEH (generous gift from B.D.H.), GSK-3β, phospho-GSK-3β, p42/p44-MAPK, phospho-
p42/p44-MAPK (Cell Signaling Technology, Inc, Beverly, Mass), BKCa-α, BKCa-β1,
GAPDH, or actin C-11 (Santa Cruz Biotechnology, Santa Cruz, Calif).
Fatty Acid Metabolism
Heart cytosolic fractions (2 mg protein/mL) were incubated with [1-14C]14,15-EET (100
μmol/L) as described.17 Products were extracted and analyzed by high-performance liquid
chromatography.18 Epoxide hydrolase activity was calculated as the rate of 14,15-DHET
produced/mg protein/min at 37°C. Neonatal cardiomyocyte cell culture media, adult plasma,
and heart perfusate were analyzed for epoxy and dihydroxy fatty acid derivatives of AA and
linoleic acid (LA) using established HPLC/MS/MS methods.12,19
Transthoracic Echocardiography, Assessment of Heart Anatomy
Two-dimensional guided M-mode echocardiography was performed using an HDI 5000
echocardiograph as described.20 sEH null mice and WT littermate controls were then
euthanized and hearts were removed, dissected, and weighed.
Isolated-Perfused Hearts
Hearts were perfused in the Langendorff mode as described.12 Hearts were perfused with
buffer for a 40-minute stabilization period then subjected to 20 minutes global no-flow
ischemia, followed by 40 minutes reperfusion. For some experiments, hearts were stabilized
for 20 minutes, then perfused with either the putative pan-EET receptor antagonist 14,15-
epoxyeicosa-5(Z)-enoic acid (14,15-EEZE, 10 to 100 nmol/L), 8,9-EET (1 μmol/L), 11,12-
EET (1 μmol/L), 14,15-EET (1 μmol/L), the sarcolemmal KATP (sarcKATP) and mitochondrial
KATP (mitoKATP) channel inhibitor glibenclamide (GLIB, 1 μmol/L), the selective
mitoKATP channel inhibitor 5-hydroxydecanoate (5-HD, 100 to 200 μmol/L), the PI3K
inhibitors wortmannin (200 nmol/L) or LY294002 (5 μmol/L), the p42/p44-MAPK kinase
(MEK) inhibitor PD98059 (10 μmol/L), the BKCa channel inhibitor paxilline (10 μmol/L), or
vehicle for 20 minutes, then subjected to 20 minutes ischemia and 40 minutes reperfusion in
the presence of antagonist or inhibitors. Recovery of contractile function was taken as left
ventricular developed pressure (LVDP) at the end of reperfusion expressed as a percentage of
preischemic LVDP. To determine the amount of infarction, after 2 hour reperfusion, hearts
were incubated with a 1% solution of 2,3,5-triphenyl-tetrazolium chloride (TTC) dissolved in
Krebs–Henseleit buffer at 37°C for 10 minutes, then fixed in formalin and cut into thin cross-
sectional slices. The area of infarction was quantified by measuring stained (red, live tissue)
and unstained (white, necrotic) regions. LDH activity was assessed in heart perfusates using a
commercially available assay (Roche Applied Sciences).
Statistical Analysis
Values are expressed as mean ± SEM. Data were analyzed by ANOVA or Student t test using
SYSTAT software (SYSTAT Inc). Values were considered significantly different if P<0.05.
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Initial Characterization of sEH Null Hearts
Northern analysis with the sEH cDNA probe (Figure 1a) and immunoblotting with an sEH-
specific antibody (Figure 1b) revealed that sEH null hearts lacked expression of sEH at both
the mRNA and protein levels. Cytosolic fractions from WT hearts rapidly converted 14,15-
EET to 14,15-DHET (rate: 9.6 ± 0.6 nmol DHET formed/mg cytosolic protein/min; Figure
1c). In contrast, cytosolic fractions from sEH null hearts were unable to convert 14,15-EET to
14,15-DHET (Figure 1d), indicating reduced capacity for EET hydrolysis. To further assess
fatty acid metabolism from endogenous lipid pools, we measured levels of CYP epoxygenase-
derived products of AA and LA in plasma and cardiomyocyte cell culture media from sEH
null and WT mice by HPLC/MS/MS. The sEH null mice had elevated plasma levels of fatty
acid epoxides and depressed plasma levels of fatty acid diols relative to WT controls (see online
supplement). Thus, the ratio of plasma EETs to DHETs was higher in sEH null compared with
WT mice (Figure 1e). Similarly, the ratio of plasma epoxyoctadecenoic acids (EpOME) to
dihydroxyocta-decenoic acids (DHOMEs) was higher in sEH null mice relative to WT controls
(Figure 1e). Similar results were obtained for cardiomyocyte cell culture media (Figure 1f and
online supplement). Levels of EETs and DHETs in cardiac perfusates before and after ischemia
in both WT and sEH null mice were at or below detection limits of the HPLC/MS/MS assay,
and therefore could not be quantified. Taken together, these data indicate that sEH null mice
exhibit altered fatty acid epoxide metabolism in cardiomyocytes in vitro and in the systematic
circulation in vivo.
Heart Anatomy and Baseline Function
The Table summarizes anatomic and functional characteristics in sEH null and WT hearts.
There were no significant differences between the two groups in heart or individual chamber
weights, echocardiographic dimensions, or fractional shortening, heart rate, or hemodynamic
parameters under basal conditions. These data indicate that sEH null hearts are anatomically
and functionally normal at baseline.
Cardiac Performance After Ischemia/Reperfusion in Perfused Hearts
Isolated-perfused sEH null hearts had normal baseline contractile function, measured as LVDP
(Figure 2a; Table). Hearts from sEH null mice had significantly improved postischemic
recovery of LVDP compared with hearts from WT littermate controls. The improved function
was evident within 10 minutes of reperfusion and persisted throughout the recovery period
(Figure 2a). At 40 minutes reflow, LVDP recovery was significantly higher in sEH null (51 ±
3%) than WT hearts (22 ± 2%) (Figure 2b and 2c; Table). There were no differences between
sEH null and WT hearts in time-to-onset of ischemic contracture (16.0 ± 0.7 minutes versus
15.0 ± 0.5 minutes, P = 0.15) or maximal ischemic contracture (73 ± 4 cm H2O versus 70 ± 6
cm H2O, P = 0.55). After 20 minutes of global ischemia and 120 minutes of reperfusion, sEH
null hearts had significantly less infarction than WT hearts (Figure 2d and 2e). Consistent with
these results, there was a significant reduction in LDH activity in sEH null heart perfusate
compared with WT during reperfusion (Figure 2f).
To determine whether the improved postischemic functional recovery in sEH null hearts was
mediated by CYP epoxygenase metabolites, we conducted experiments in the presence of
14,15-EEZE. This putative pan-EET receptor antagonist caused a small reduction in
postischemic LVDP recovery in WT mice at high concentrations (Figure 2c). Importantly,
14,15-EEZE completely abolished the improved postischemic recovery of LVDP in sEH null
mice; recovery of LVDP at 40 minutes reflow was 52 ± 5% in the absence of 14,15-EEZE, 23
± 4% in the presence of 10 nmol/L 14,15-EEZE, and 16 ± 3% in the presence of 100 nmol/L
14,15-EEZE (Figure 2c). Thus, percent LVDP recovery was comparable in the two genotypes
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after treatment with 14,15-EEZE. Moreover, perfusion of WT hearts with physiologically
relevant concentrations (1 μmol/L) of 8,9-EET, 11,12-EET, or 14,15-EET resulted in improved
postischemic functional recovery compared with perfusion with vehicle (LVDP = 33.6 ± 8.5%,
36.5 ± 5.2%, 27.6 ± 1.6%, and 20.4 ± 1.0%, respectively, n = 4 to 8 per group, P<0.05 versus
vehicle for each EET regioisomer). Together, these data indicate that the cardioprotective
phenotype in sEH null mice is mediated by CYP epoxygenase metabolites, presumably EETs.
Role of MAPK and PI3K Pathways in Postischemic Functional Recovery
To determine whether the MAPK signaling pathway was involved in the cardioprotective
mechanism, we examined the phosphorylation status of p42/p44-MAPK in WT and she null
hearts and examined the effect of the MEK inhibitor PD98059 on postischemic functional
recovery. We did not observe differences between sEH null and WT mice in phosphorylation
of p42/p44-MAPK (Figure 3a). Moreover, perfusion with PD98059 did not block the improved
functional recovery in sEH null hearts (Figure 3b). Together, these data indicate that the MAPK
pathway is not involved in the cardioprotective phenotype of sEH null mice.
To determine the role of the PI3K signaling cascade in the cardioprotective response, we
conducted experiments in the presence or absence of the PI3K inhibitors wortmannin or
LY294002. Neither inhibitor had a significant effect on baseline LVDP in our model system
(data not shown). Perfusion with either wortmannin or LY294002 for 20 minutes before
ischemia had no effect on postischemic LVDP recovery in WT hearts; however, both inhibitors
completely abolished the improved postischemic functional recovery in sEH null hearts (Figure
4a). Thus, percent LVDP recovery at 40 minutes reperfusion was comparable in the two
genotypes after treatment with either wortmannin or LY294002 (Figure 4a). These data suggest
the involvement of the PI3K cascade in the cardioprotective phenotype observed in sEH null
mice.
To further assess downstream targets in the PI3K cascade, we examined the phosphorylation
status of GSK-3β in WT and sEH null hearts at baseline, during ischemia, and during
reperfusion. There were no significant differences in the expression of phospho–GSK-3β
between WT and sEH null hearts under basal conditions (Figure 4b). Interestingly, levels of
phospho–GSK-3β were significantly higher in sEH null hearts compared with WT hearts at 5
minutes of reperfusion (Figure 4b). Likewise, the ratio of phospho–GSK-3β to total GSK-3β
expression was significantly greater in sEH null hearts than in WT hearts during early
reperfusion (Figure 4d). These differences were no longer present during late reperfusion. The
increased phosphorylation of GSK-3β during early reperfusion in sEH null mice was
significantly attenuated by the PI3K inhibitor wortmannin (200 nmol/L; Figure 4c and 4d).
Together with recent data on the central role of GSK-3β activation in cardioprotection,21 these
data suggest one possible mechanism for the observed postischemic recovery in sEH null mice.
Role of K+ Channels in Postischemic Functional Recovery
To determine whether KATP channels were involved in the cardioprotective mechanism, we
conducted experiments in the presence or absence of the sarcKATP and mitoKATP inhibitor
GLIB or the selective mitoKATP inhibitor 5-HD. Neither GLIB nor 5-HD had significant effects
on baseline LVDP (data not shown). Perfusion with either GLIB or 5-HD for 20 minutes before
ischemia completely abolished the improved postischemic functional recovery in sEH null
hearts (Figure 5a). Thus, percent LVDP recovery at 40 minutes reperfusion was comparable
in the two genotypes after treatment with either GLIB or 5-HD (Figure 5a).
To examine the potential role of BKCa channels in the cardioprotective phenotype, we
examined the effects of the specific BKCa inhibitor paxilline (100 μmol/L) on postischemic
LVDP. Administration of paxilline abolished the improved postischemic functional recovery
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in sEH null hearts (Figure 5b). There were no differences in expression of the BKCa-β1 subunit
between WT and sEH null hearts (Figure 5c). Expression of the BKCa-α subunit was low-
undetectable in both WT and sEH null hearts, consistent with a recent publication.22
Discussion
Cardiac CYP epoxygenases convert AA to biologically active EETs that have well established
effects within the cardiovascular system.12,18 The activity of these compounds is terminated
mainly through conversion to less active DHETs by sEH.2 Recent studies demonstrate that
CYP epoxygenase-derived eicosanoids can affect cardiomyocyte function11,13,14 and
improve postischemic LVDP recovery.12,14,15 In addition, EET biosynthesis is enhanced in
stenosed coronary arteries23 and during cardiac ischemia/reperfusion injury.24 The data
presented herein provide further evidence that EETs are involved in the cardioprotective
response. We demonstrate, for the first time, that targeted disruption of the Ephx2 gene leads
to improved recovery of left ventricular function and reduced infarction after ischemia.
Moreover, the putative EET receptor antagonist 14,15-EEZE abolishes the cardio-protection
in these mice specifically implicating EETs in this process. Taken together, these data suggest
that EETs have important functional effects in the ischemic heart and that augmentation of
EET levels by inhibition of sEH may represent a novel approach to the treatment of ischemic
heart disease.
Heart anatomy and basal contractile function are similar in sEH null and WT mice, suggesting
that disruption of the Ephx2 gene has no detrimental cardiac effects under normal conditions.
However, sEH null mice have altered fatty acid metabolism compared with WT mice at
baseline. Indeed, increased LA and AA epoxide:diol ratios were found in the circulation and
in cardiomyocyte cell culture media from sEH null mice. Moreover, conversion of 14,15-EET
to 14,15-DHET was absent in heart cytosolic fractions from sEH null mice. The majority of
endogenous EETs (>85%) are esterified to membrane glycerophospoholipids where they are
generally considered inactive until their release.25 The cardiac effects of sEH disruption
occurred only after ischemia, presumably attributable to enhanced release of EETs from
phospholipid stores. In this regard, ischemia has been shown to activate cytosolic
phospholipase A2, leading to the release of bioactive eicosanoids from glycerophospholipids.
26 The results in the current article are consistent with our recent findings that mice
overexpressing human CYP2J2 in the heart have normal heart anatomy and function at
baseline, but have elevated cardiomyocyte EET levels and improved postischemic functional
recovery.12
AA can be metabolized by CYP epoxygenases and CYP ω-hydroxylases to products that have
different physiologic effects. For example, EETs have potent vasodilatory properties and 20-
HETE has vasoconstrictive effects.1 Changes in expression or activity of specific CYP
enzymes can alter the delicate balance between EETs and 20-HETE. For example, recent data
demonstrates that inhibition of CYP ω-hydroxylases results in reduction of infarction after
ischemic injury, suggesting that 20-HETE has detrimental effects within the heart.27,28 These
studies highlight the complexity of the CYP enzyme system and emphasize the role of different
CYP metabolites in cardioprotection. Many CYP inhibitors lack isoform specificity and also
may have effects in other signaling pathways. By targeting sEH, our study can more directly
address the role of CYP epoxygenase products in the cardiovascular system and minimize
ambiguity in deciphering the relative importance of individual enzymes and their metabolites.
The sEH null hearts have reduced levels of LA diols (DHOMEs) which have been shown to
cause adverse cardiac effects, such as mitochondrial dysfunction29 and altered cardiac
electrical activity.30 Thus, increased EETs and decreased DHOMEs are beneficial to the
cardiovascular system and could both be responsible for the observed cardioprotection in sEH
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null mice. To determine the relative importance of EETs in this model, we used 14,15-EEZE,
which has been shown to be selective for inhibition of EET effects within the cardiovascular
system.31 At the highest dose, treatment with 14,15-EEZE caused a small reduction in
postischemic LVDP recovery in WT mouse hearts consistent with a role for EETs in this
process. Importantly, 14,15-EEZE abolished the improved postischemic LVDP recovery in
sEH null mouse hearts, indicating that the cardioprotective effects were mediated by EETs.
Although it is possible that 14,15-EEZE has effects that are unrelated to EET antagonism,32
these results are consistent with both current and previous data demonstrating that addition of
EETs to heart perfusates before ischemia results in improved postischemic functional recovery
in both rats and mice.12,14
Hydrolysis of EETs by sEH is dependent on both regio-and stereoselective parameters.33
14,15-EET is the preferred sEH substrate, and 5,6-EET is an extremely poor substrate for this
enzyme.33 The lipid metabolite profiles observed in cardiomyocyte cultures in sEH null mice
showed altered epoxide:diol ratios for the 8,9-, 11,12-, and 14,15-EET regioisomers, but not
for the 5,6-EET regioisomer. These data are consistent with the known substrate preferences
of sEH.
The lack of difference in p42/p44-MAPK activation between sEH null and WT mice is in sharp
contrast to our previous study, where phosphorylation of p42/p44 was enhanced in CYP2J2
transgenic mice and administration of PD98059 completely blocked the improved function
recovery.12 This suggests that different mechanisms may underlie the cardioprotection in sEH
null and CYP2J2 transgenic mice, both of which have increased cardiac EETs. Possible reasons
for these differences include: (1) CYP2J2 overexpression was restricted to cardiomyocytes in
the transgenic mice whereas sEH disruption occurred in both cardiomyocytes and endothelial
cells; and (2) DHETs are reduced in sEH null mice but increased in CYP2J2 transgenic mice.
Activation of the PI3K signaling pathway targets multiple cellular functions, including
survival, proliferation, and vesicle trafficking.34 The PI3K signaling pathway has been shown
to be involved in cardioprotective responses after ischemia/reperfusion.35,36 Signaling
through PI3K promotes a prosurvival mechanism involving recruitment of downstream kinases
such as GSK-3β.34,35 The fact that two structurally different PI3K inhibitors attenuate the
improved postischemic LVDP recovery in sEH null mice provides strong evidence for
enhanced activation of this pathway. In this regard, we observed increased phospho–
GSK-3β expression during early reperfusion in sEH null hearts, a phenomenon which was
abolished by PI3K inhibition. Consistent with these data, cell culture studies have demonstrated
that EETs activate the PI3K-Akt pathway.8 Recent evidence suggests that convergence of
multiple cardioprotective signaling pathways onto GSK-3β may represent an integrated
mechanism of cellular protection.21 It was purposed that this convergence targets the
mitochondrial permeability transition pore (MPTP) complex limiting its opening.21 Inhibition
of MPTP induction early during reperfusion has cardioprotective effects.35
A large body of research suggests a role for KATP channels in cardioprotection.37
Cardiomyocyte studies have demonstrated that EETs enhance both sarcKATP and mitoKATP
channel activities.11,12 In the current study, administration of either the sarcKATP channel
inhibitor glibenclamide or the mitoKATP channel inhibitor 5-HD attenuated the improved
postischemic recovery of sEH null hearts. The precise identity of the mitoKATP channel has
yet to be determined, therefore it is unknown whether EETs directly target these channels or
work through upstream signals such as PI3K. Recent work has suggested the role of BKCa
channels in protection against ischemia/reperfusion injury.38 EETs are known activators and
ω-HETEs are known inhibitors of these channels in vascular smooth muscle cells.1,5 Newly
identified KCa channels in cardiac mitochondria (mitoKCa) are thought to work in concert with
mitoKATP and other mitochondrial proteins to mediate cardioprotection.38,39 Our experiments
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demonstrate that the BKCa channel inhibitor paxilline abolished the improved postischemic
functional recovery in sEH hearts, suggesting a role for this channel in the cardioprotective
mechanism. Activation of the channels might protect the myocardium by increasing
mitochondrial K+ uptake and, in turn, reducing Ca2+ overload, with a net effect of protecting
mitochondrial function.38,39
We postulate that the enhanced functional recovery observed in the sEH null mice entails
modulation of both PI3K and mitochondrial K+ channels. Figure 6 shows a schematic of the
proposed mechanisms whereby disruption of sEH leads to cardioprotection via increasing EET
levels.
Recent epidemiologic data suggests an association between polymorphisms in the genes
encoding CYP2J2, CYP2C8, CYP2C9, and EPHX2 and cardiovascular disease risk in humans
suggesting the relevance of the CYP epoxygenase pathway in the heart.40–42 The data in the
current manuscript is consistent with an important modulatory effect of CYP-derived
eicosanoids in general and sEH in particular in cardioprotection. The present study
demonstrates that targeted disruption of Ephx2 in mice has no effect on basal heart anatomy
and function but results in improved postischemic recovery of LVDP. Taken together, these
data suggest that manipulating sEH activity may represent a novel therapeutic approach to
management of ischemic heart disease in humans.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Identification and initial characterization of sEH null mice. a, Northern blot showing absence
of sEH transcripts in sEH null heart RNA, n=4. b, Immunoblots demonstrating lack of sEH
protein expression in hearts of sEH null mice and abundant expression in WT mice. c and d,
Representative HPLC chromatograms showing 14,15-EET metabolism to 14,15-DHET by
cytosolic fractions prepared from hearts of WT (c) and sEH null (d) mice. e, Ratio of
arachidonic acid (EET:DHET) and linoleic acid (EpOME:DHOME) epoxides to diols in
plasma from sEH null and WT mice. f, Ratio of arachidonic acid and linoleic acid epoxides to
diols in cardiomyocyte cell culture media from sEH null and WT mice. Values shown are mean
± SEM; n=4 to 5 per group; *P<0.05 vs WT.
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Postischemic recovery of left ventricular function and infarction in sEH null and WT mice. a,
LVDP in sEH null and WT mice. Values shown are mean ± SEM; n = 28 to 42; *P<0.05 vs
WT. b, Recovery of LVDP at 40 minutes reperfusion expressed as a percentage of baseline
LVDP in hearts from sEH null and WT mice. c, Effects of the putative EET receptor antagonist
14,15-EEZE on postischemic recovery of LVDP in WT and sEH null hearts. Values represent
mean ± SEM; n = 4 to 12; ‡P<0.05 vs vehicle control of same genotype; *P<0.05 vs WT. d,
Representative pictures of TTC staining in sEH null and WT hearts. TTC stains surviving
tissues red and leaves infarcted areas white. e, Quantification of infarct size. Values represent
mean ± SEM; n = 5; *P<0.05 vs WT. f, LDH activity in perfusates from WT and sEH null
hearts. Values represent mean ± SEM; n = 6 to 12 per group; ‡P<0.05 vs baseline of same
genotype; *P<0.05 vs WT at same time point.
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Activation status of p42/p44-MAPK in WT and sEH null hearts. a, Representative
immunoblots showing expression of phospho-p42/p44-MAPK and total p42/p44-MAPK in
hearts after 5 minutes reperfusion. Similar results were obtained at other time points. b, Effects
of MEK inhibition on postischemic recovery of LVDP in WT and sEH null hearts. Hearts were
administered vehicle or PD98059 (10 μmol/L) before ischemia. Values represent mean ± SEM;
n = 4 to 6 per group; *P<0.05 vs WT.
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Role of PI3K and GSK-3β in postischemic recovery of LVDP in WT and sEH null hearts. a,
Hearts were administered vehicle, wortmannin (100 nmol/L), or LY294002 (5 μmol/L) before
ischemia. Values represent mean ± SEM; n = 4 to 12; ‡P<0.05 vs vehicle control of same
genotype; *P<0.05 vs WT. b, Representative immunoblots showing cardiac expression of
phospho-GSK-3β and total GSK-3β. c, Representative immunoblots showing expression of
phospho–GSK-3β and total GSK-3β at 5 minutes reperfusion after wortmannin (100 nmol/L)
administration. d, Ratio of phospho–GSK-3β to total GSK-3β after 5 minutes reperfusion in
the presence or absence of wortmannin. Values represent mean ± SEM; n = 4 per group;
*P<0.05 vs WT.
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Role of cardiac K+ channels in postischemic recovery of LVDP in WT and sEH null hearts. a,
Effects of KATP inhibitors on postischemic recovery of LVDP in WT and sEH null hearts.
Hearts were administered vehicle, GLIB (1 μmol/L), or 5-HD (100, 200 μmol/L) before
ischemia. b, Effects of BKCa inhibition on postischemic recovery of LVDP in WT and sEH
null hearts. Hearts were administered vehicle or paxilline (10 μmol/L) before ischemia. Values
represent mean ± SEM; n = 4 to 12 per group; *P<0.05 vs WT; ‡P<0.05 vs vehicle control of
same genotype. c, Representative immunoblots showing expression of BKCa-α, BKCa-β1, and
GAPDH in hearts from WT and sEH null mice.
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Schematic of proposed mechanisms of cardioprotection in sEH null mice. EETs activate K+
channels and the PI3K pathway leading to cardioprotection.
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Table
Cardiac Parameters in sEH Null and WT Mice
Baseline WT (n = 12 to 45) sEH null (n = 12 to 45)
Body weight, g 28.3 ± 2.2 26.5 ± 1.4
Heart weight, mg 137.7 ± 9.5 128.4 ± 6.3
Heart/body wt, mg/g 5.3 ± 0.2 4.9 ± 0.2
Left ventricle free wall weight, mg 107.3 ± 7.5 97.5 ± 4.7
Right ventricle free wall weight, mg 24.3 ± 2.1 24.5 ± 2.0
Left atrium weight, mg 3.5 ± 0.4 3.5 ± 0.4
Right atrium weight, mg 2.6 ± 0.2 2.9 ± 0.3
M-mode echocardiogram
 Left ventricular end-diastolic dimension, mm 2.8 ± 0.1 3.0 ± 0.1
 Left ventricular end-systolic dimension, mm 1.2 ± 0.2 1.4 ± 0.1
 Fractional shortening, % 48.3 ± 0.4 52.6 ± 4.2
 Septal wall thickness, mm 1.5 ± 0.5 1.4 ± 0.1
 Posterior wall thickness, mm 1.6 ± 0.2 1.4 ± 0.1
 HR, conscious, beats/min 669 ± 0.7 640 ± 57
Isolated perfused heart, preischemic
 LVDP, cmH2O (Baseline) 108 ± 6 97 ± 5
 Rate of contraction, dP/dtmax, cm H2O/msec (Baseline) 6096 ± 497 5635 ± 364
 Rate of relaxation, −dP/dtmin, cm H2O/msec (Baseline) −4461 ± 349 −3990 ± 270
 HR, perfused, beats/min (Baseline) 366 ± 19 338 ± 9
Isolated perfused heart, postischemic
 LVDP, cmH2O (R40) 23 ± 2 48 ± 4*
 Rate of contraction, dP/dtmax, cm H2O/msec (R40) 1511 ± 213 2942 ± 270*
 Rate of relaxation, −dP/dtmin, cm H2O/msec (R40) −1034 ± 151 −1907 ± 164*
 HR, perfused, beats/min (R40) 315 ± 27 317 ± 12
Body and heart weights were determined using an analytical balance; dimensions and percent fractional shortening were assessed by transthoracic
echocardiography in conscious mice; hemodynamic parameters were measured in isolated-perfused hearts. Values are mean ± SEM,
*
P<0.05 vs WT. HR indicates heart rate.
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